S&A FDA Report (defunct)

If you’ve subscribed to S&A FDA Report (defunct), please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.

Investment Performance

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Quality Of Writing/Analysis

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Value For Price

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Customer Service

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote
guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

2 Comments
Inline Feedbacks
View all comments
sushiman
Guest
sushiman
October 3, 2009 9:04 am

I’m an Alliance Member over at Stansberry & Associates, so I’ve seen all their products and used most of them. So far (a few months now), the S&A FDA Report has done the best. I first got in with a great, if somewhat accidental, trade on Dendreon. I read about it one of the free update newsletters, got in just before it spiked, and made 150% on my money in about four days. (I actually did better than Dr. Huang on that one, as I just bought the stock instead of using the hedged option play that he was recommending, but he made money on it too.) That was good enough to convince me to try the service.

Since then most of his recommendations have made money for me. I haven’t taken all of them, but the ones I have taken have either spiked and then stopped back out at a small loss, or else gone for substantial gains. MYRX is the straight stock buy one; I got in at about $4.75 and got out a few weeks later at $6.25 or so. I think his strategy of buying before major FDA decisions on pipeline drugs is a good one. Not all of the drugs get approved, of course, but he seems to have a pretty good feel for which ones will and won’t. An example of making money on one that didn’t is his OSIR play; it involved buying one option at $10 and selling two more at $5 (to help offset the cost) when the stock was at $14. Now, post-FDA decision, the stock is trading around $6.50, which means the position is working precisely as he predicted. Again, he’s not always right, but generally seems to make good calls. And when he’s wrong it’s not for too much money, whereas when he’s right there are generally good double-digit gains.

If you decide to use his service I recommend setting your stop-loss at something less than 25%. I use 20% or 10%, depending.

No customer service rating since I’ve never had to use customer service for this newsletter.

Add a Topic
28
Add a Topic
3022
Add a Topic
146
Nils
Guest
Nils
January 5, 2010 1:19 pm

Lost on all his recommendations and could not afford to stay in for very long.
Big mouth no results sorry.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info